EyePoint, Inc.
- EYPT · Nasdaq
- Laboratory Analytical Instruments
- Watertown, MA
- 214 employees
- CIK 0001314102
Updated from SEC filings through
Top things to know
Executives
-
Jay S. Duker President and CEO 4, 2026-07-14 -
George Elston Chief Financial Officer 4, 2026-08-24 -
Ramiro Ribeiro Chief Medical Officer 4, 2026-07-02 -
Michael Campbell Chief Commercial Officer 10-K, 2026-03-05
EyePoint, Inc. is a U.S. public company in laboratory analytical instruments (SIC 3826), headquartered in Watertown, MA. It trades as EYPT on Nasdaq. Revenue was $31.4M in the fiscal year ending December 31, 2025, -27.5% from the year before. It reported about 214 employees. Jay S. Duker is President and CEO.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $31.4M 10-K, 2026-03-05 | $43.3M 10-K, 2026-03-05 | $46.0M 10-K, 2025-03-06 | $41.4M 10-K, 2024-03-08 | $36.9M 10-K, 2023-03-10 |
| Operating income | -$243M 10-K, 2026-03-05 | -$146M 10-K, 2026-03-05 | -$75.1M 10-K, 2025-03-06 | -$99.6M 10-K, 2024-03-08 | -$55.3M 10-K, 2023-03-10 |
| SG&A | $51.7M 10-K, 2026-03-05 | $52.5M 10-K, 2026-03-05 | $51.8M 10-K, 2025-03-06 | $60.3M 10-K, 2024-03-08 | $53.1M 10-K, 2023-03-10 |
| Net income | -$232M 10-K, 2026-03-05 | -$131M 10-K, 2026-03-05 | -$70.8M 10-K, 2025-03-06 | -$102M 10-K, 2024-03-08 | -$58.4M 10-K, 2023-03-10 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Jay S. Duker | President and CEO | 4, 2026-07-14 |
| George Elston | Chief Financial Officer | 4, 2026-08-24 |
| Ramiro Ribeiro | Chief Medical Officer | 4, 2026-07-02 |
| Michael Campbell | Chief Commercial Officer | 10-K, 2026-03-05 |
| Wendy DiCicco | Board member (per proxy) bio: Chair of the Audit Committee and member of the Compensation Committee and the Governance and Nominating Committee | DEF 14A, 2026-04-27 |
| Reginald J. Sanders, M.D., FASRS | Director | 10-K, 2026-03-05 |
What EyePoint, Inc. does
EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology (Durasert E™) for sustained intraocular drug delivery.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 86.2 million (as of July 31, 2026) | 10-Q, August 5, 2026 |
|---|---|---|
| Public float | $643M (as of June 30, 2025) | 10-K, March 5, 2026 |
| Latest proxy statement | Meeting June 18, 2026 (filed April 27, 2026) | DEF 14A, April 27, 2026 |
| Auditor | Deloitte & Touche LLP (Boston, Massachusetts) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| August 18, 2026 | Karen L. Zaderej Director | Buy | 10,600 | $52K | Form 4, August 18, 2026 |
| June 30, 2026 | Ramiro Ribeiro Chief Medical Officer | Sale | 4,875 | $73K | Form 4, July 2, 2026 |
| April 17, 2026 | Ramiro Ribeiro Chief Medical Officer | Sale | 2,437 | $37K | Form 4, April 20, 2026 |
| March 16, 2026 | Jay S. Duker President and CEO | Buy | 1,500 | $20K | Form 4, March 16, 2026 |
| March 4, 2026 | Ramiro Ribeiro Chief Medical Officer | Sale | 2,438 | $44K | Form 4, March 5, 2026 |
| February 17, 2026 | Ramiro Ribeiro Chief Medical Officer | Sale | 2,437 | $37K | Form 4, February 18, 2026 |
| January 5, 2026 | Ramiro Ribeiro Chief Medical Officer | Sale | 42,544 | $728K | Form 4, January 7, 2026 |
| December 4, 2025 | Nancy Lurker Director | Sale | 9,300 | $141K | Form 4, December 5, 2025 |
Recent 8-K events
- 8-K filed 2026-10-19
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 2.05 Costs associated with exit or disposal activities (restructuring)
- Item 8.01 Other events
- 8-K filed 2026-10-19
- Item 8.01 Other events
- 8-K filed 2026-09-10
- Item 8.01 Other events
- 8-K filed 2026-08-17
- Item 8.01 Other events
- 8-K filed 2026-08-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-30
- Item 8.01 Other events
- 8-K filed 2026-07-17
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2026-06-22
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-14
- Item 8.01 Other events
- 8-K filed 2026-05-06
- Item 2.02 Results of operations and financial condition (earnings release)
Frequently asked questions about EyePoint, Inc.
- What does EyePoint, Inc. do?
- In its own words, from Item 1 of its 10-K: "EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology (Durasert E™) for sustained intraocular drug delivery."
- What is EyePoint, Inc.'s revenue?
- $31.4M for the fiscal year ending December 31, 2025, from its 10-K filed March 5, 2026.
- Is EyePoint, Inc. profitable?
- EyePoint, Inc. reported net income of -$232M for the fiscal year ending December 31, 2025.
- How many employees does EyePoint, Inc. have?
- About 214 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of EyePoint, Inc.?
- Jay S. Duker, President and CEO, as named in a 4 filed July 14, 2026.
- Who is the CFO of EyePoint, Inc.?
- George Elston, Chief Financial Officer, as named in a 4 filed August 24, 2026.
- Where is EyePoint, Inc. headquartered?
- Watertown, MA.
- What is EyePoint, Inc.'s stock ticker?
- EYPT on Nasdaq.
- What industry is EyePoint, Inc. in?
- Laboratory Analytical Instruments, SIC code 3826.
- What is EyePoint, Inc.'s website?
- eyepoint.bio.
- When does EyePoint, Inc. report earnings next?
- November 12, 2026. Source: pg_earnings_events.
- Is EyePoint, Inc. a public company?
- Yes. EyePoint, Inc. files with the SEC under CIK 0001314102 and trades as EYPT.
- Who audits EyePoint, Inc.?
- Deloitte & Touche LLP, Boston, Massachusetts, as named in its latest annual report (10-K).
- How many shares of EyePoint, Inc. are outstanding?
- 86.2 million shares as of July 31, 2026, from its 10-Q filed August 5, 2026.
- What is EyePoint, Inc.'s public float?
- $643M as of June 30, 2025, as reported on the cover of its 10-K filed March 5, 2026.
- When is EyePoint, Inc.'s annual shareholder meeting?
- June 18, 2026, per its proxy statement (DEF 14A) filed April 27, 2026.
- Have EyePoint, Inc. insiders traded stock recently?
- Since November 11, 2025, officers and directors reported 8 open-market sales worth about $1.1M and 2 purchases worth about $72K on Forms 4 and 5. The most recent: Karen L. Zaderej (Director) bought 10,600 shares on August 18, 2026.